Philip Morris Seeks FDA Nod for ZYN as Lower-Risk Alternative

Event summary

  • Philip Morris presented scientific evidence to the FDA's TPSAC on January 22, 2026, seeking a Modified Risk Tobacco Product (MRTP) designation for its ZYN nicotine pouches.
  • The proposed claim states that switching from cigarettes to ZYN lowers the risk of six critical health conditions, including mouth cancer and heart disease.
  • FDA noted that youth nicotine pouch use prevalence is currently low and that the proposed claim did not increase intentions to use ZYN among young adults.
  • ZYN received marketing authorization through the Premarket Tobacco Product Authorization (PMTA) pathway in January 2025.

The big picture

Philip Morris's pursuit of an MRTP designation for ZYN aligns with its broader strategy to shift towards smoke-free products. The company aims to reduce the health risks associated with smoking by promoting alternatives like ZYN, which has already received marketing authorization. This move is part of a larger industry trend towards harm reduction and regulatory scrutiny of tobacco products.

What we're watching

Regulatory Approval
Whether the FDA will grant the MRTP designation for ZYN, allowing Philip Morris to communicate reduced-risk claims to adult smokers.
Market Adoption
The pace at which smokers transition from cigarettes to ZYN if the MRTP designation is approved.
Competitive Dynamics
How other tobacco companies may respond to Philip Morris's push for reduced-risk product authorization.